SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Msellem Mwinyi I.)
 

Sökning: WFRF:(Msellem Mwinyi I.) > A cluster randomise...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005640naa a2200685 4500
001oai:DiVA.org:uu-369728
003SwePub
008181217s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:139751108
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3697282 URI
0247 a https://doi.org/10.1186/s12916-018-1202-82 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1397511082 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Morris, Ulrikau Karolinska Institutet4 aut
2451 0a A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission.
264 c 2018-12-10
264 1b Springer Science and Business Media LLC,c 2018
338 a electronic2 rdacarrier
520 a BACKGROUND: Mass drug administration (MDA) has the potential to interrupt malaria transmission and has been suggested as a tool for malaria elimination in low-endemic settings. This study aimed to determine the effectiveness and safety of two rounds of MDA in Zanzibar, a pre-elimination setting.METHODS: A cluster randomised controlled trial was conducted in 16 areas considered as malaria hotspots, with an annual parasite index of > 0.8%. The areas were randomised to eight intervention and eight control clusters. The intervention included two rounds of MDA with dihydroartemisinin-piperaquine and single low-dose primaquine 4 weeks apart in May-June 2016. Primary and secondary outcomes were cumulative confirmed malaria case incidences 6 months post-MDA and parasite prevalences determined by PCR 3 months post-MDA. Additional outcomes included intervention coverage, treatment adherence, occurrence of adverse events, and cumulative incidences 3, 12, and 16 months post-MDA.RESULTS: Intervention coverage was 91.0% (9959/10944) and 87.7% (9355/10666) in the first and second rounds, respectively; self-reported adherence was 82.0% (881/1136) and 93.7% (985/1196). Adverse events were reported in 11.6% (147/1268) and 3.2% (37/1143) of post-MDA survey respondents after both rounds respectively. No serious adverse event was reported. No difference in cumulative malaria case incidence was observed between the control and intervention arms 6 months post-MDA (4.2 and 3.9 per 1000 population; p = 0.94). Neither was there a difference in PCR-determined parasite prevalences 3 months post-MDA (1.4% and 1.7%; OR = 1.0, p = 0.94), although having received at least the first MDA was associated with reduced odds of malaria infection (aOR = 0.35; p = 0.02). Among confirmed malaria cases at health facilities, 26.0% and 26.3% reported recent travel outside Zanzibar in the intervention and control shehias (aOR ≥ 85; p ≤ 0.001).CONCLUSIONS: MDA was implemented with high coverage, adherence, and tolerability. Despite this, no significant impact on transmission was observed. The findings suggest that two rounds of MDA in a single year may not be sufficient for a sustained impact on transmission in a pre-elimination setting, especially when the MDA impact is restricted by imported malaria. Importantly, this study adds to the limited evidence for the use of MDA in low transmission settings in sub-Saharan Africa.TRIAL REGISTRATION: ClinicalTrials.gov, NCT02721186 (registration date: March 29, 2016).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
653 a Adherence
653 a Coverage
653 a Dihydroartemisinin-piperaquine
653 a Effectiveness
653 a Elimination
653 a Low transmission
653 a Malaria
653 a Mass drug administration
653 a Safety
653 a Single low-dose primaquine
7001 a Msellem, Mwinyi I4 aut
7001 a Mkali, Humphrey4 aut
7001 a Islam, Atiqul4 aut
7001 a Aydin-Schmidt, Beritu Karolinska Institutet4 aut
7001 a Jovel, Irina4 aut
7001 a Shija, Shija Joseph4 aut
7001 a Khamis, Mwinyi4 aut
7001 a Ali, Safia Mohammed4 aut
7001 a Hodzic, Lamija4 aut
7001 a Magnusson, Ellinor4 aut
7001 a Poirot, Eugenie4 aut
7001 a Bennett, Adam4 aut
7001 a Sachs, Michael Cu Karolinska Institutet4 aut
7001 a Tarning, Joel4 aut
7001 a Mårtensson, Andreas,d 1963-u Uppsala universitet,Internationell barnhälsa och nutrition4 aut0 (Swepub:uu)andma331
7001 a Ali, Abdullah S4 aut
7001 a Björkman, Andersu Karolinska Institutet4 aut
7102 a Karolinska Institutetb Internationell barnhälsa och nutrition4 org
7730 t BMC Medicined : Springer Science and Business Media LLCg 16:1q 16:1x 1741-7015
8564 u https://doi.org/10.1186/s12916-018-1202-8y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1271276/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-018-1202-8
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-369728
8564 8u https://doi.org/10.1186/s12916-018-1202-8
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:139751108

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy